Discover

XFOR
X4 Pharmaceuticals, Inc.
4.08
2 x 3.32
2 x 5.22
bid
ask
-
0.58
12.53%
2 @ 04:00 PM
4.20 +0.12 (2.82%)
Ytd2.12%
1y119.62%
4.06
day range
4.70
1.35
52 week range
4.83
Open4.64Prev Close4.67Low4.06High4.70Mkt Cap385.30M
Vol806.77KAvg Vol592.69KEPS-2.07P/EN/AForward P/E-1.23
Beta0.39Short Ratio8.64Inst. Own67.66%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg4.09200-d Avg3.801yr Est3.05

XFOR News

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
globenewswire.com
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directo

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im

benzinga.com
Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Ta

Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with

Earnings Scheduled For May 6, 2026
benzinga.com
Earnings Scheduled For May 6, 2026

benzinga.com
X4 Pharmaceuticals Q1 EPS $(0.16) Beats $(0.20) Estimate, Sales $2.708M Miss $3.200M Estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analy

benzinga.com
X4 Pharma Says EC Grants Marketing Authorization For XOLREMDI Capsules For Treatment Of Patients Wit

- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Piv

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
X4 Pharmaceuticals Q4 EPS $(0.22) Beats $(0.38) Estimate, Sales $2.568M Beat $1.733M Estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.22) per share which beat the analy

benzinga.com
Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12

Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wedn

benzinga.com
Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10

Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises th

benzinga.com
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)

benzinga.com
X4 Pharmaceuticals Q3 EPS $(0.69) Beats $(0.82) Estimate, Sales $1.765M Miss $1.901M Estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.69) per share which beat the analy

benzinga.com
X4 Pharmaceuticals Prices $135M Public Offering Of 45.86M Common Shares At $2.90 Each To Advance Pha

And, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 sha

benzinga.com
X4 Pharmaceuticals Launches Of An Underwritten Public Offering Of Its Common Stock; No Financial Ter

X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improv

benzinga.com
X4 Pharmaceuticals Announces Strategic Restructuring With 50% Workforce Reduction Expected To Delive

Organizational restructuring including a 50% reduction in workforce that is anticipated to result in

benzinga.com
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9

Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers th

benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $3.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)

benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
X4 Pharmaceuticals Announced Private Placement In Public Equity Financing Of Approximately $60M

$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga.com
X4 Pharmaceuticals Enters Purchase Agreement With Lincoln Park; Can Sell Up To $40M In Stock

https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000162828025032627/xfor-20250623.htm

benzinga.com
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $7

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)

benzinga.com
Earnings Scheduled For May 1, 2025

benzinga.com
Earnings Preview For X4 Pharmaceuticals

Top 3 Health Care Stocks That May Rocket Higher In April
benzinga.com
Top 3 Health Care Stocks That May Rocket Higher In April

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com
Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views

benzinga.com
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $1.5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR

benzinga.com
Cantor Fitzgerald Reiterates Overweight on X4 Pharmaceuticals, Maintains $3 Price Target

Cantor Fitzgerald analyst Kristen Kluska reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Overw

benzinga.com
X4 Pharmaceuticals Q4 2024 GAAP EPS $(0.20) Misses $(0.17) Estimate, Sales $1.43M Beat $1.04M Estima

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.20) per share which missed the ana

benzinga.com
Earnings Scheduled For March 25, 2025

benzinga.com
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $1.5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com
X4 Pharmaceuticals Cuts Workforce by 30% to Focus on Mavorixafor for Chronic Neutropenia, Scales Bac

X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases

Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

benzinga.com
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $1.5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR

benzinga.com
X4 Pharmaceuticals Secures Licensing Deal With Norgine To Bring Mavorixafor To Europe, Australia, An

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and com

benzinga.com
X4 Pharmaceuticals To Present Trial-In-Progress Poster On Phase 3 Study Of Mavorixafor In Chronic Ne

X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases

benzinga.com
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)

benzinga.com
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $4

Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers th

benzinga.com
X4 Pharmaceuticals Q3 2024 GAAP EPS $(0.18) Misses $(0.17) Estimate, Sales $560.00K Miss $1.69M Esti

X4 had $135.8 million in cash, cash equivalents, restricted cash, and short-term marketable securiti